Compare

MedinCell S.A./€MEDCL

1D1W1M3M6MYTD1Y5YMAX

About MedinCell S.A.

MedinCell S.A. is a pharmaceutical company focused on the development of long-acting injectable therapeutics. Operating in the healthcare industry, MedinCell specializes in drug delivery technology that combines global health needs with the potential for improved patient adherence. The company is known for its proprietary BEPO technology, which allows for controlled and sustained release of medication. Founded in 2002 and headquartered in Jacou, France, the company works on a pipeline of therapeutic solutions across various segments, including pain management, contraception, and mental health. MedinCell's strategic position is reinforced by its collaborative partnerships and its innovative approach to addressing unmet medical needs with affordable healthcare solutions.
Ticker
€MEDCL
Sector
Health
Primary listing
PAR
Employees
141
Headquarters
Jacou, France
Website
www.medincell.com

MedinCell S.A. Metrics

BasicAdvanced
€1B
-
-€0.94
0.91
-

What the Analysts think about MedinCell S.A.

Analyst ratings (Buy, Hold, Sell) for MedinCell S.A. stock.
Analyst projections of the future price of MedinCell S.A. stock.

Bulls say / Bears say

UZEDY’s US sales reached $85 million in Q3 2026, up 96% year on year, prompting Teva to raise its full-year outlook to $290–310 million. MedinCell earns mid- to high-single-digit royalties, so continued sales growth should lift recurring income. (Business Wire)
FDA approval of WELTRUZA gives MedinCell a second commercial product using its BEPO technology and another potential royalty stream. Its once-monthly olanzapine injection avoids post-injection monitoring, while MedinCell is also eligible for milestone payments. (BioSpace)
The development pipeline offers potential growth beyond the two marketed products: MedinCell reported 15 active formulation programmes, including eight funded by partners, and expects its AbbVie programme to enter clinical development in 2027. A Gates Foundation grant is also supporting malaria work towards first-in-human testing. (Euronext)
MedinCell remains loss-making as it invests for growth: FY2025–26 operating loss was €20.8 million and net cash outflow from operations was €24.6 million. Operating expenses rose 17% to €45 million, leaving execution dependent on future revenue growth. (Euronext)
The six-month contraception programme has been delayed after changes to its expected regulatory pathway, and the company was still assessing the impact. That postpones a potential pipeline opportunity and adds uncertainty to its timing. (Euronext)
MedinCell’s commercial revenues rely on Teva’s sales and launch execution, while its stated royalty rate on WELTRUZA is only mid- to high-single digits. The company has noted that uptake will depend on reimbursement, physician adoption and patient access. (BioSpace, Quartr)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.

MedinCell S.A. Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

MedinCell S.A. Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing MedinCell S.A.

Funds
Fund name
Fund size
€MEDCL weighting
iShares Healthcare Innovation€2B78
$1.2B0.11%
iShares Healthcare Innovation£DRDR
$1.3B0.11%
iShares Healthcare Innovation$HEAL
$1.3B0.11%
iShares Ageing Population$AGED
$953M0.10%
iShares Ageing Population£AGES
$953M0.10%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.